Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Lymphoma 272Lymphoma, Large B-Cell, Diffuse 259Leukemia, Lymphocytic, Chronic, B-Cell 189Lymphoma, Non-Hodgkin 187Lymphoma, Mantle-Cell 165Lymphoma, Follicular 164Lymphoma, B-Cell, Marginal Zone 115Leukemia 94Burkitt Lymphoma 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Waldenstrom Macroglobulinemia 77Lymphoma, B-Cell 62Recurrence 51Hodgkin Disease 50Lymphoma, Large-Cell, Immunoblastic 44Lymphoma, Large-Cell, Anaplastic 20Leukemia, Myeloid, Acute 20Myelodysplastic Syndromes 18Intraocular Lymphoma 15Hematologic Neoplasms 15Neoplasms 14Dendritic Cell Sarcoma, Interdigitating 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Multiple Myeloma 13Leukemia, Hairy Cell 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Neoplasms, Plasma Cell 10Leukemia, Prolymphocytic 10Lymphoma, T-Cell 9Leukemia, Myelomonocytic, Chronic 9

Interventions

fludarabine 4fludarabine phosphate 3Cyclophosphamide 3thymoglobulin 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Mesna 1Melphalan 1Erythrocyte Count 1Dexamethasone 1Clofarabine 1Busulfan 1Bortezomib 1Blood Transfusion 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thalassemia × Rituximab × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡